In individuals with mild cognitive impairment (MCI) or dementia, evidence of cerebral amyloid and tau accumulation accompanying neurodegeneration is necessary to confirm the diagnosis of Alzheimer’s disease (AD)1. This evidence concerns the gene MAPT and dementia.